A Trial of Pharmacist Management of Oral Anticoagulation THerapy Versus Enhanced Usual CARe in the communitY for AF

Last updated: October 23, 2024
Sponsor: Cedars-Sinai Medical Center
Overall Status: Active - Recruiting

Phase

4

Condition

Dysrhythmia

Chest Pain

Atrial Fibrillation

Treatment

Oral anticoagulant

Clinical Study ID

NCT04907825
00000850
  • Ages > 60
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This is a prospective, open-label, cluster-randomized controlled trial of 400 participants (aged 60 years or older, with additional stroke risk factors and 'actionable' undertreated AF) from a total of 40 retail and outpatient community pharmacies. Participants will be randomized (by pharmacy) to either to an intervention arm of pharmacist-led OAC management versus an enhanced usual care arm, wherein physicians receive notification of 'actionable' AF and patients are advised to schedule a physician clinic visit. The primary objective will be to determine the difference in proportion of patients with 'actionable AF' receiving guideline concordant OAC therapy at 3 months in those randomized to intervention arm versus control arm.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age > 60 years

  2. Men (CHADS-VASc score ≥2) AND Women (CHADS-VASc score ≥3)

  3. AF and not on OAC therapy but eligible

  4. AF and on sub-optimal or inappropriate OAC therapy

  5. Written informed consent

Exclusion

Exclusion Criteria:

  1. AF on optimal OAC therapy

  2. OAC required for other conditions (i.e. DVT/PE, PCI in prior year, left ventricularthrombus, etc.)

  3. Currently taking two antiplatelet agents

  4. Uncontrolled hypertension (defined as SBP ≥160 mmHg x 2 BP readings measured atscreening)

  5. End-stage renal disease (CrCl <15 ml/min or dialysis)

  6. Major surgery in prior month (defined as surgery requiring general anesthesia andovernight inpatient hospital stay)

  7. History of "major bleeding" in prior year (defined as overt bleeding at criticalsite including intracranial, intraspinal, intraocular, pericardial, GI bleed, bleedrequiring hospitalization, bleed resulting in ≥20 g/L drop in hemoglobin orrequiring transfusion of ≥2 units packed cells)

  8. Excess alcohol intake (≥8 alcoholic drinks/week)

  9. Inability to read or understand English or Spanish

  10. Participants considered unreliable by the Investigator or designated pharmacy teammember concerning the requirements of follow-up, or those with foreshortened lifeexpectancy precluding 3-month follow-up

  11. Severe cognitive impairment (≥5 errors on the Short Portable Mental StatusQuestionnaire)

  12. Pregnant women

Study Design

Total Participants: 400
Treatment Group(s): 1
Primary Treatment: Oral anticoagulant
Phase: 4
Study Start date:
January 01, 2023
Estimated Completion Date:
August 31, 2025

Study Description

Oral anticoagulation therapy for stroke prevention in AF is safe and effective but under-utilized. Optimal delivery of existing therapies would prevent AF-related stroke. Therefore alternative strategies to increase adherence to current guidelines for OAC use for AF stroke prevention should be explored.

Accumulating data indicate that pharmacist-led or pharmacist-collaborative care in cardiovascular disease monitoring, risk factor control, and medication optimization leads to greater adherence to guideline-directed targets and improved outcomes.

In this prospective, open-label, cluster-randomized controlled trial the investigators intend to enroll 400 participants (aged 60 years or older, with additional stroke risk factors and 'actionable' undertreated AF) from a total of 40 retail and outpatient community pharmacies in Los Angeles. Participants will be randomized (by pharmacy) to either to an intervention arm of pharmacist-led OAC management versus an enhanced usual care arm, wherein physicians receive notification of 'actionable' AF and patients are advised to schedule a physician clinic visit. The primary objective will be to determine the difference in proportion of patients with 'actionable AF' receiving guideline concordant OAC therapy at 3 months in those randomized to intervention arm versus control arm. Secondary outcomes include: patient satisfaction with pharmacist services (at 3 months), pharmacists' perspective on study implementation (at study end), and OAC adherence (at 1 year). In an exploratory aim, the investigators will assess healthcare utilization and clinical outcomes at 1 year.

This research will generate new knowledge on an innovative, and potentially sustainable stroke prevention strategy to increase evidence-based use of OAC therapy in patients with AF.

Connect with a study center

  • Cedars-Sinai Medical Center

    Los Angeles, California 90048
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.